Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 4/2010

01-03-2010 | Adis Drug Evaluation

Sitagliptin

A Review of its Use in the Management of Type 2 Diabetes Mellitus

Author: Sohita Dhillon

Published in: Drugs | Issue 4/2010

Login to get access

Abstract

Sitagliptin (Januvia™, Glactiv®, Tesavel®) is a dipeptidyl peptidase-4 inhibitor indicated for the treatment of type 2 diabetes mellitus. Oral sitagliptin as mono-therapy or combination therapy was generally well tolerated and improved glycaemic control in well designed clinical trials in patients with type 2 diabetes. Glycosylated haemoglobin (HbA1c) levels were significantly reduced with sitagliptin monotherapy relative to voglibose monotherapy or placebo, and with sitagliptin as initial combination therapy with metformin or pioglitazone relative to monotherapy with these agents or placebo. Moreover, sitagliptin monotherapy was noninferior to metformin monotherapy in terms of the reduction in HbA1c levels. Significant reductions in HbA1c levels, relative to background therapy, were also observed with sitagliptin add-on therapy to ongoing treatment with thiazolidinediones, sulfonylureas or insulin with or without metformin, or metformin alone. In terms of the reduction in HbA1c levels as add-on treatment to metformin, sitagliptin was noninferior to glipizide and generally did not differ from rosiglitazone, and as add-on treatment to pioglitazone, it did not differ significantly from metformin. Sitagliptin had a low risk of hypoglycaemia (except when used in combination with agents that may be associated with hypoglycaemia, such as sulfonylureas or insulin) and was generally weight-neutral. Although additional comparative data and longer-term studies with glycaemic and clinical outcomes are required to definitively position sitagliptin relative to other antihyperglycaemic agents, current evidence suggests that it is a useful treatment option for patients with type 2 diabetes, with potential advantages including oral administration, a generally weight-neutral effect and a low risk of hypoglycaemia.
Literature
1.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2009 Jan; 32 Suppl. 1: S62–7CrossRef
2.
3.
Rosenstock J, Zinman B. Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 2007 Apr; 14(2): 98–107PubMedCrossRef
4.
Campbell RK. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus. Ann Pharmacother 2007 Jan; 41(1): 51–60PubMed
5.
Ahren B. Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. Diabetes Care 2007 Jun; 30(6): 1344–50PubMedCrossRef
6.
Inzucchi SE, McGuire DK. New drugs for the treatment of diabetes: part II. Incretin-based therapy and beyond. Circulation 2008 Jan 29; 117(4): 574–84PubMedCrossRef
7.
8.
Kim D, Wang L, Beconi M, et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro [1,2,4] triazolo [4,3-a] pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl) butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005 Jan 13; 48(1): 141–51PubMedCrossRef
9.
Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels following an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006 Nov; 91(11): 4612–9PubMedCrossRef
10.
Herman GA, Stevens C, Van Dyck K, et al. Pharmaco-kinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005 Dec; 78(6): 675–88PubMedCrossRef
11.
Bergman AJ, Stevens C, Zhou YY, et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 2006 Jan; 28(1): 55–72PubMedCrossRef
12.
Herman GA, Bergman A, Liu F, et al. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol 2006 Aug; 46(8): 876–86PubMedCrossRef
13.
Migoya EM, Miller JL, Larson PJ, et al. Sitagliptin, a selective DPP-4 inhibitor, and metformin have complementary effects to increase active GLP-1 concentrations [abstract no. 0111]. Diabetologia 2007; 50 Suppl. 1: S52
14.
Alba M, Sheng D, Guan Y, et al. Sitagliptin 100mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement. Curr Med Res Opin 2009 Oct; 25(10): 2507–14PubMedCrossRef
15.
Nonaka K, Tsubouchi H, Okuyama K, et al. Effects of once-daily sitagliptin on 24-h glucose control following 4 weeks of treatment in Japanese patients with type 2 diabetes mellitus. Horm Metab Res 2009 Mar; 41(3): 232–7PubMedCrossRef
16.
Kasper A, Vilsbøll T, Knop FK, et al. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, improves the insulin secreting capacity of the b-cells in subjects with type 2 diabetes mellitus: a randomized trial [abstract no. 605-P]. 69th Scientific Sessions of the American Diabetes Association; 2009 Jun 5-9; New Orleans (LA)
17.
Brazg R, Xu L, Dalla Man C, et al. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and b-cell function in patients with type 2 diabetes. Diabetes Obes Metab 2007; 9(2): 186–93PubMedCrossRef
18.
Marfella R, Barbieri M, Grella R, et al. Effects of vilda-gliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations. J Diabetes Complications. Epub 2009 Mar 3
19.
DeFronzo RA, Okerson T, Viswanathan P, et al. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008 Oct; 24(10): 2943–52CrossRef
20.
Bloomfield DM, Krishna R, Hreniuk D, et al. A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects. J Clin Pharmacol 2009 Aug; 49(8): 937–46PubMedCrossRef
21.
Bergman A, Mistry GC, Luo WL, et al. Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. Biopharm Drug Dispos 2007 Sep; 28(6): 307–13PubMedCrossRef
22.
Bergman A, Ebel D, Liu F, et al. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. Biopharm Drug Dispos 2007 Sep; 28(6): 315–22PubMedCrossRef
23.
24.
Vincent SH, Reed JR, Bergman AJ, et al. Metabolism and excretion of the DPP-4 inhibitor [14C]sitagliptin in humans. Drug Metab Dispos 2007; 35(4): 533–8PubMedCrossRef
25.
Bergman A, Stevens C, Yi B, et al. Lack of a clinically meaningful effect on age, gender or obesity on the pharmacokinetics of the DPP-IV inhibitor MK-0431 [abstract no. 2101-PO]. Diabetes 2005 Jun; 54 Suppl. 1: A506
26.
Migoya EM, Stevens CH, Bergman AJ, et al. Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin. Can J Clin Pharmacol 2009 Winter; 16(1): e165–70PubMed
27.
Bergman AJ, Cote J, Yi B, et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 2007 Jul; 30(7): 1862–4PubMedCrossRef
28.
Mistry GC, Bergman AJ, Zheng W, et al. Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects. Br J Clin Pharmacol 2008 Jul; 66(1): 36–42PubMedCrossRef
29.
Glactiv® (sitagliptin phosphate hydrate tablets): Japanese prescribing information. Osaka: Ono Pharmaceutical Co., Ltd., 2009
30.
Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006 Dec; 29(12): 2632–7PubMedCrossRef
31.
Mohan V, Yang W, Son HY, et al. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract 2009 Jan; 83(1): 106–16PubMedCrossRef
32.
Nonaka K, Kakikawa T, Sato A, et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008 Feb; 79(2): 291–8PubMedCrossRef
33.
Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006; 49(11): 2564–71PubMedCrossRef
34.
Aschner P, Katzeff HL, Guo H, et al. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab 2010 Mar 1; 12(3): 252–61PubMedCrossRef
35.
Iwamoto Y, Tajima N, Kadowaki K, et al. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. Diabetes Obes Metab. Epub 2010 Jan 7
36.
Barzilai N, Mahoney EM, Guo H, et al. Sitagliptin is well tolerated and leads to rapid improvement in blood glucose in the first days of monotherapy in patients aged 65 years and older with T2DM [abstract no. 587-P plus poster]. 69th Scientific Sessions of the American Diabetes Association; 2009 Jun 5-9; New Orleans (LA)
37.
Chan JC, Scott R, Arjona Ferreira JC, et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008 Jul; 10(7): 545–55PubMedCrossRef
38.
Aschner P, Lunceford J, Williams-Herman D. Once-daily sitagliptin monotherapy provides effective glycemic control over 54 weeks and is well tolerated in patients with type 2 diabetes [abstract no. 2181-PO]. 67th Scientific Sessions of the American Diabetes Association; 2007 Jun 22-26; Chicago (IL)
39.
Goldstein BJ, Feinglos MN, Lunceford JK, et al. on behalf of the sitagliptin 036 study group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007 Aug; 30(8): 1979–87PubMedCrossRef
40.
Yoon KH, Shockey JR, Temg R, et al. Initial combination therapy with sitagliptin and pioglitazone improves glycaemic control and measure of b-cell function compared with pioglitazone alone in patients with type 2 diabetes [abstract no. 522-P plus poster]. 69th Scientific Sessions of the American Diabetes Association; 2009 Jun 5–9; New Orleans (LA)
41.
Charbonnel B, Karasik A, Liu J, et al. on behalf of the sitagliptin study 020 group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006 Dec; 29(12): 2638–43PubMedCrossRef
42.
Kadowaki T, Tajima N, Odawara M, et al. Sitagliptin added to ongoing treatment with metformin improved glycemic control and was well tolerated in Japanese patients with type 2 diabetes [abstract no. 2135-PO]. Diabetes 2008 Jun; 57 Suppl. 1: A589–590
43.
Raz I, Chen Y, Wu M, et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin 2008 Feb; 24(2): 537–50PubMedCrossRef
44.
Nauck MA, Meininger G, Sheng D, et al. on behalf of the sitagliptin study 024 group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007 Mar; 9(2): 194–205PubMedCrossRef
45.
Scott R, Loeys T, Davies MJ, et al. on behalf of the sitagliptin study 801 group. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008 Sep; 10(10): 959–69PubMedCrossRef
46.
Dobs A, Goldstein BJ, Wieczorek L, et al. Triple combination therapy with sitagliptin, metformin, and rosiglitazone improver glyemic control in patients with type 2 diabetes [abstract no. 2152-PO]. 68th Scientific Sessions of the American Diabetes Association; 2008 Jun 6-10; San Francisco (CA)
47.
Kashiwagi A, Tajima N, Kadowaki T, et al. Sitagliptin added to ongoing treatment with pioglitazone improved glycemic control and was well tolerated in Japanese patients with type 2 diabetes [abstract no. 2136-PO]. Diabetes 2008; 57Suppl. 1: A590
48.
Rosenstock J, Brazg R, Andryuk PJ, et al. on behalf of the sitagliptin study 019 group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006 Oct; 28(10): 1556–68PubMedCrossRef
49.
Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007 Sep; 9(5): 733–45PubMedCrossRef
50.
Tajima N, Kadowaki T, Odawara M, et al. Sitagliptin added to ongoing treatment with glimepiride improved glycemic control and was well tolerated in Japanese patients with type 2 diabetes [abstract no. 2134-PO]. Diabetes 2008; 57 Suppl. 1: A589
51.
Vilsbøll T, Rosenstock J, Yki-Jarvinen H, et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2010 Feb; 12(2): 167–77PubMedCrossRef
52.
Derosa G, Maffioli P, Salvadeo SA, et al. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism. Epub 2009 Dec 14
53.
Williams-Herman D, Johnson J, Teng R, et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Curr Med Res Opin 2009 Mar; 25(3): 569–83PubMedCrossRef
54.
Qi DS, Teng R, Jiang M, et al. Two-year treatment with sitagliptin and initial combination therapy of sitagliptin and metformin provides substantial and durable glycaemic control in patients with type 2 diabetes [abstract no. 73]. Diabetologia 2008; 51 Suppl. 1: S36
55.
Karasik A, Wu M, Williams-Herman D, et al. Sitagliptin added to ongoing metformin therapy provides sustained glycemic control over 54 weeks, with a low incidence of hypoglycemia and with weight loss [abstract no. 523-P]. 67th Scientific Sessions of the American Diabetes Association; 2007 Jun 22–26; Chicago (IL)
56.
Maegawa H, Kashiwagi A, Tajima N, et al. Sitagliptin added to ongoing treatment with pioglitazone study up to 52 weeks in Japanese patients with T2DM [abstract no. 910]. Diabetologia 2008; 51 Suppl. 1: S365
57.
Iwamoto Y, Nonaka K, Okada A, et al. Dose-response relationship for glycaemic efficacy, safety and tolerability of sitagliptin after 12 weeks of treatment in Japanese patients with type 2 diabetes mellitus [abstract no. 0888 plus poster]. Diabetologia 2007 Sep; 50 Suppl. 1: S366. Plus poster presented at the 43rd Annual Meeting of the European Association for the Study of Diabetes; 2007 Sep 18–21; Amsterdam
58.
Hanefeld M, Herman GA, Wu M, et al. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin 2007 Jun; 23(6): 1329–39PubMedCrossRef
59.
Scott R, Wu M, Sanchez M, et al. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as mono-therapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 2007 Jan; 61(1): 171–80PubMedCrossRef
60.
American Diabetes Association. Standards of medical care in diabetes-2009. Diabetes Care 2009 Jan; 32 Suppl. 1: S13–61CrossRef
61.
IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med 2006 Jun; 23(6): 579–93CrossRef
62.
Merck. Monotherapy study in patients with type 2 diabetes mellitus [ClinicalTrials.gov identifier NCT00087516]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://​clinicaltrials.​gov [Accessed 2010 Feb 23]
63.
64.
Williams-Herman D, Round E, Swern AS, et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocr Disord 2008; 8: 14PubMedCrossRef
65.
Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009 Apr; 25(4): 1019–27PubMedCrossRef
66.
67.
68.
Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007 Jan 2; 115(1): 114–26PubMedCrossRef
69.
70.
The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008 Jun 12; 358(24): 2554–9
71.
The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008 Jun 12; 358(24): 2560–72CrossRef
72.
UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published erratum appears in Lancet 1998 Nov 7; 352 (9139): 1558]. Lancet 1998 Sep 12; 352(9131): 837–53CrossRef
73.
Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008 Oct 9; 359(15): 1577–89PubMedCrossRef
74.
Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 2009 Jan 20; 53(3): 298–304PubMedCrossRef
75.
Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009 Jan; 32(1): 193–203PubMedCrossRef
76.
77.
78.
Barnett AH. New treatments in type 2 diabetes: a focus on the incretin-based therapies. Clin Endocrinol (Oxf) 2009 Mar; 70(3): 343–53CrossRef
79.
Pratley RE, Gilbert M. Targeting incretins in type 2 diabetes: role of GLP-1 receptor agonists and DPP-4 inhibitors. Rev Diabet Stud 2008 Summer; 5(2): 73–94PubMedCrossRef
80.
Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007 Jul 11; 298(2): 194–206PubMedCrossRef
81.
Wajchenberg BL. b-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007 Apr; 28(2): 187–218PubMedCrossRef
82.
Riche DM, East HE, Riche KD. Impact of sitagliptin on markers of beta-cell function: a meta-analysis. Am J Med Sci 2009 May; 337(5): 321–8PubMedCrossRef
83.
Bethel MA, Gree J, Califf RM, et al. Rationale and design of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) [abstract no. 2152-PO]. 69th Scientific Sessions of the American Diabetes Association; 2009 Jun 5–9; New Orleans (LA)
84.
Merck. Sitagliptin cardiovascular outcome study (TECOS) [ClinicalTrials.gov identifier NCT00790205]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://​clinicaltrials.​gov [Accessed 2009 Dec 2]
85.
Schwarz B, Gouveia M, Chen J, et al. Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy. Diabetes Obes Metab 2008 Jun; 10 Suppl. 1: 43–55PubMedCrossRef
86.
Brandle M, Chen J, Alemao E, et al. Cost-effectiveness of adding sitagliptin vs. an sulfonylurea in Swiss patients with type 2 diabetes inadequately controlled on metformin monotherapy [abstract no. 1095]. Diabetologia 2008; 51 Suppl. 1: S446
87.
Minshall M, St. Charles M, Pandya B, et al. The cost-effectiveness of pioglitazone compared with sitagliptin: an economic evaluation using a validated economic model from a third party payer perspective in the USA [abstract no. PDB19]. Value Health 2007 Nov/Dec; 10(6): A259
88.
Ahrén B. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin-diabetes control and potential adverse events. Best Pract Res Clin Endocrinol Metab 2009 Aug; 23(4): 487–98PubMedCrossRef
89.
Metadata
Title
Sitagliptin
A Review of its Use in the Management of Type 2 Diabetes Mellitus
Author
Sohita Dhillon
Publication date
01-03-2010
Publisher
Springer International Publishing
Published in
Drugs / Issue 4/2010
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/11203790-000000000-00000

Other articles of this Issue 4/2010

Drugs 4/2010 Go to the issue

Adis Drug Profile

Fospropofol

Therapy in Practice

Pharmacological Management of Low Back Pain

Review Article

Pharmacotherapy Options for Locally Advanced and Advanced Cervical Cancer

Adis Drug Profile

Tolvaptan

Leading Article

Sodium-Glucose Co-Transport Inhibitors

Adis Drug Profile

Pilsicainide